Plasma Ci inhibitor either in the platelet suspension medium or on the surface of the platelets could account for only from 6.5 to 16% of the total antigen measured in the solubilized platelets. Upon functional studies, platelets contained 84±36 ng (SD) of Ci inhibitor activity in 10' platelets. As assessed by the CELISA, platelet Ci inhibitor antigen was immunochemically identical to plasma and purified Ci inhibitor. In contrast, the mean concentration of platelet Ci inhibitor antigen in platelets from four patients with classical hereditary angioedema was 8.3 ng/10 platelets (range, 5.3 to 11.3 ng/10 platelets). 25 and 31% of the total platelet Ci inhibitor was secreted without cell lysis from normal platelets after exposure to collagen (20 pg/ml) and thrombin (1 U/ml), respectively, and this secretion was blocked by metabolic inhibitors. Platelet subcellular fractionation showed that platelet Ci inhibitor resided mostly in alpha-granules, similar to the location of platelet fibrinogen. Thus, human platelets contained Ci inhibitor, which became available by platelet secretion. The identification of platelet Ci inhibitor suggests that platelets may modulate the activation of the proteins of early blood coagulation and the classical complement pathways.
Introduction
Understanding of the role of human platelets in the activation of plasma coagulation proteolysis has been furthered by the recognition that four plasma hemostatic cofactors-fibrinogen (1-3), Factor V (4-8), Factor VIII-related antigen (9-1 1), and high molecular weight kininogen (12)-are contained within platelets. Similarly, the details of inhibition of coagulation and fibrinolysis reactions on or close to the platelet surface can begin to be formulated since three of the major plasma purification was done by performance of gel filtration over Sepharose CL-6B. Fractions containing C! INH antigen by counterimmunoelectrophoresis (30) constituted a single peak of -220,000 M, by gel filtration. By nonreduced SDS gel electrophoresis (31) , purified Cl INH was a single component (M, 107,000) (Fig.' 1) . Upon'reduction with 2% beta-mercaptoethanol there was a slight decrease in size (Mr 100,000) of the major band and the appearance of two minor components (M, 62,000 and 46,000), which constituted <5% of the Coomassie Blue stained material by densitometer scanning. These minor components probably represented degradation products of Ci INH as previously reported (29) . As shown by immunodiffusion (32) the purified protein was not contaminated with human serum albumin and transferrin.
Protein determinations were performed by the methods of Bradford (33) using crystalline bovine serum albumin as the standard, and of Scopes (34 (40) from platelet-rich plasma. Platelets (1.14 X 10'0 platelets) from platelet-rich plasma were separated from plasma by centrifugation, gel-filtration over Sepharose 2B, and recentrifugation. After solubilization of the platelet pellet with 0.2% Triton X-100, the supernatant was placed on a Concanavalin ASepharose column in order to obtain a partially purified platelet extract. The eluate after introduction of I M alpha-methylmannoside was collected and concentrated to 1/1,000 of the starting volume of plateletrich plasma. The amount of plasma Cl INH contaminating the platelet extract was estimated by determination of the recovery of 125I-Cl INH added to the starting platelet-rich plasma in the final material.
Functional Cl INH activity in the platelet glycoprotein extract was determined by the ability of the partially purified platelet material to neutralize the amidolytic activity of purified kallikrein (27) . 60 Ml of platelet extract, pretreated for 2 h at 230C with methylamine to inactivate alpha-2-macroglobulin (four parts platelet extract to one part 0.2 M methylamine, pH 7.4 [27] ) was incubated with 0.3 Mg of purified kallikrein (7.8 X 10-1 M) (27) . At precise intervals (5, 15, 25, 35 min), 10 Ml of the mixture was removed and the residual kallikrein amidolytic was determined as previously reported (27) . The amount of Cl INH activity in the platelet extract was calculated by an integrated second-order reaction equation: A second 7.5-ml aliquot of identically washed platelets was centrifuged at 12,000 g in an Eppendorf Centrifuge (Brinkmann Instruments, Inc., Westbury, NY), and the supernatant was incubated 1:1 with anti-Cl INH antibody prepared as described above. After completion of the incubations and a 4-min centrifugation at 12,000 g in the centrifuge, the antibody adsorbed with platelets was compared with that adsorbed with supernatant on the CELISA by use of known amounts of purified Cl INH antigen in order to determine a standard curve.
Platelet secretion studies. Fresh platelets washed by albumin density gradient centrifugation and gel filtration were divided into four aliquots of from 5 to 7 ml each in 16 X 95 mm flat-bottomed polystyrene tubes (No. 62.492; Sarstedt, Inc., Princeton, NJ) and placed into a 370C water bath. The sample for total platelet Cl INH was solubilized by 0.5% Triton X-100 for 45 min at 370C. The sample for platelet supernatant Cl INH was obtained by the centrifugation at 12,000 g of an aliquot of platelets for 4 min followed by collection of the supernatant and incubation for 45 min at 370C. Washed platelets used in agonist studies were incubated for 30 min at 370C in the absence or presence of the combined metabolic inhibitors antimycin A (15 ug/ ml), 2-deoxy-D-glucose (30 mM), and D-gluconic acid -lactone (10 mM) (43, 44). At the end of the incubation, the tubes were placed into a 370C water bath with stirring at 1,200 rpm, and collagen (20 Mg/ml) or thrombin (1 U/ml) was added. After 10 min, the agonisttreated samples were centrifuged at 12,000g for 4 min and the supernatants were collected. At the end of the secretion experiment, 0.1-ml aliquots were removed from the total, supernatant, agonisttreated, and agonist-plus-metabolic inhibitor-treated samples, and mixed with an equal volume of a mixture of one part 77 mM EDTA, pH 7.4 and nine parts ethanol. These samples were later assayed for total adenine nucleotide (ADP and ATP) content according to the method of Holmsen et al. (45) . Similarly, 0.2 ml of each sample was obtained for the determination of platelet lactic dehydrogenase loss according to the method of Wroblewski and Ladue (46) . Platelet alpha-granule secretion was assessed by measurement of low affinity platelet Factor 4 by the method of Rucinski et al. (47) . The remaminng materal was used to assay for CI INH antigen by the CELISA. All samples were stored at -70'C until assay. Each experiment used combined washed platelets from two normal donors. Percentage secretion (or loss) was determined by the ratio of the supernatant of the agonist-treated specimen to the total platelet lysate after the value of the nonactivated platelet supernatant was subtracted from both. All values represent the percentage of the total amount of each constituent found in the platelet. Washed platelets were also used to prepare Triton-insoluble cytoskeletons according to the method of Tuszynski et al. (48) .
Platelet subcellular fractionation. Platelet subcellular fractionation was performed according to the technique of Fukami et al. (49) . In each preparation, platelet-rich plasma from 450 ml blood was collected, made 5 mM with EDTA, and pelleted by centrifugation at 3,000 g for 10 min at 4VC. The platelet pellet was suspended in 30 mM Hepes, 5 mM EDTA, and 0.15 M NaCl, pH 6.5. After it was washed by centrifugation twice more at 3,000 g for 10 min at 40C, the pellet was resuspended in 40 ml of the same medium containing 20 MM rotenone, 5 mM 2-deoxy-D-glucose, and 10 mM D-gluconic acid -lactone and incubated at 37°C for 20 min. Then, 3 mg nagarse and 20 mg ATP were mixed into the suspension at 37°C. 5 min later, 20 mg soybean trypsin inhibitor was added to neutralize the nagarse, and the platelets were centrifuged at 3,000 g for 10 min at 4°C. The pellet was then resuspended in 25 ml of 0.01 M Hepes, I mM EDTA, and 0.25 M sucrose, pH 7.4 and homogenized twice in a French pressure cell (50) at 500 pounds per square inch, with one centrifugation in between the two homogenizations so that only the unbroken cells were subjected to the second homogenization. 5-ml of the combined homogenate was set aside and 20 ml was used for fractionation. Differential centrifugation of the homogenate resulted in the isolation of four fractions: F1, 1,000 g X 22 min pellet; F2, 12,000 g X 20 min pellet; F3, 100,000 g X 60 min pellet; and F4, the 100,000 g supernate. The granule fraction, F2, was then divided in half, and one half was applied to a 0.8 to 2.0 M sucrose step gradient in 0.2-M increments (51) . After centrifugation at 100,000 g for 60 min, five distinct areas were collected: A, 0.25-1.0 M sucrose; B, 1.0-1.3 M sucrose; C/D, 1.3-1.8 M sucrose; E, 1.8-2.0 M sucrose; and F, a pellet. Before assay, fractions F4 and A-E of the F2 were dialyzed against 0.01 M Hepes, 1 mM EDTA, pH 7.4, lyophilized, and resuspended in 5 ml of the dialysis buffer. All fractions were treated with 0.5% Triton X-100 before assay. CI INH antigen was assayed by CELISA. ,B-N-acetyl-glycosaminidase was assayed by the technique of Day et al. (52) . Fibrinogen was assayed by EID (37 (Fig. 4) . (27) , the inactivation of kallikrein must have arisen from C1 INH. This C1 INH activity had to arise from platelets since only 2% 'of the total amount of C I INH in the platelet extract could be estimated to be' from plasma contamination by independent radiolabeled '251-Ci INH tracer experiments.'The concentration of C1 INH in the platelet extract was 9.2±4 X 108 M (mean±SD for 15 determinations) for 1.14 X 10'0 platelets. This value suggested that platelets contain 84 ng functional CT INH/108 platelets (range 48 to 121 ng/108 platelets). (Table II) . At a high dose of each agonist, collagen (20 ,g/ml) induced secretion of 25% of the total platelet C! INH antigen, and thrombin (I U/ml) induced secretion of 31% of the total platelet C! INH antigen. This amount of the total antigen secreted for each agonist was less than that seen for a platelet dense granule marker-total adenine nucleotides-and a platelet alpha-granule marker-low affinity platelet Factor 4. With collagen, 45% of the total adenine nucleotides and 52% of the total low affinity platelet Factor 4 were secreted. With thrombin, 68% of both markers was secreted. washed lysed platelets were subjected to differential centrifugation, the largest amount, as indicated by the area under the graph, of platelet C1 INH antigen and of fibrinogen antigen emerged in the 12,000 g pellet (fraction F2), a fraction enriched with platelet granules and mitochondria (Fig. 6) .
In an attempt to separate further the components of the granule fraction, the F2 was subjected to sucrose density ultracentrifugation (Fig. 7) . In six experiments, the mean±SEM recovery for total protein was 88±8%; C1 INH antigen, 96±14%; fibrinogen antigen, 90±9%; ,B-N-acetyl-glucosaminidase, 77±5%; and serotonin, 98±4.4%. Upon sucrose density ultracentrifugation, 80% (48) , suggesting that it does not become a cytoskeletal component after platelet activation. The secretion of only 25 to 40% of the total platelet content of a high molecular weight hemostatic cofactor contained within platelet alpha-granules, in contrast to low affinity platelet Factor 4 (47), has been noted previously for platelet fibronectin (54), high molecular weight kininogen (12, 55) , and von Willebrand factor (1 1).
Platelet subcellular fractionation studies indicate that 80% of platelet CT INH in the unstimulated platelet is found in those granule fractions that contain alpha-granules (Fig. 7) . The relative absence of any significant amount of the protein in the F pellet on the sucrose gradient (Fig. 7) , the area where platelet serotonin is largely concentrated, excludes the possibility that platelet CT INH is a dense granule protein. Although 20% of platelet CT INH from the F2 fraction was found in the A fraction (soluble portion) of the sucrose gradient (Fig. 7) , the presence of an equally large amount of platelet fibrinogen in this fraction suggests that some granules may have been lysed in resuspension of the F2 pellet (Fig. 6 ) and transfer of it to the gradient for ultracentrifugation. Further confirmation of a platelet alpha-granule localization for platelet CT INH in the unstimulated platelet requires studies on the total content of platelet CT INH in gray platelets (56).
The platelet CT INH level for 3 X 101 platelets/ml plasma is 183 ng, which constitutes 0.08% of the plasma level of 230 ,ug/ml. This value is similar to that which has been determined for platelet alpha-2-macroglobulin (0.04%) (13), alpha-l-antitrypsin (0.007%) (13, 14) , and alpha-2-antiplasmin (0.03%) (20). However, since platelets are concentrated within the fibrin clot, local concentrations of secreted platelet CT INH may exceed physiologic plasma amounts. If platelets secrete their granules by exocytosis and platelet granules are about one-tenth of the volume of platelets (the volume of 10"l platelets is 0.7 ml [57] ), the concentration of platelet CT INH in granules at the platelet surface during secretion could be -2.6 mg/ml for 300,000 platelets/Al, 10 times its concentration in plasma. In contrast, activated platelets from the patients with hereditary angioedema could only achieve levels of CT INH similar to the concentration of C1 INH in normal plasma. This interpretation enhances the physiologic potential of platelet CT INH, since localized concentrations of the magnitude achievable by normal platelets may effectively promote inhibition of contact-phase proteases (22) (23) (24) (25) . Recent studies on platelet high molecular weight kininogen indicate that at least a portion equal to that secreted into the suspending medium also becomes expressed on the activated platelet surface (55) . This finding suggests that high local concentrations of platelet forms of plasma proteins may be achieved on the activated platelet surface. The finding that platelets contain both the major cofactor (high molecular weight kininogen) (12) and inhibitor (CT INH) to contact phase activation, without containing the protease (kallikrein) (unpublished data) suggests that the platelet locus may be an important site of modulation of surface-activated defense mechanisms involved in complement activation (58, 59) 
